{"id":10627,"date":"2026-07-13T11:04:55","date_gmt":"2026-07-13T09:04:55","guid":{"rendered":"https:\/\/nexxusbio.com\/?p=10627"},"modified":"2026-08-10T16:35:36","modified_gmt":"2026-08-10T14:35:36","slug":"melanotan-ii-vyskumne-pouzitie","status":"publish","type":"post","link":"https:\/\/nexxusbio.com\/en\/melanotan-ii-vyskumne-pouzitie\/","title":{"rendered":"Melanotan II research: \u03b1-MSH and melanocortin receptors"},"content":{"rendered":"<p><strong>Melanotan II v\u00fdskum<\/strong> sa s\u00fastre\u010fuje na syntetick\u00fd cyklick\u00fd peptidov\u00fd anal\u00f3g alfa-melanocyty stimuluj\u00faceho horm\u00f3nu (\u03b1-MSH) a jeho interakcie s melanokort\u00ednov\u00fdm receptorov\u00fdm syst\u00e9mom. V odbornej literat\u00fare sa Melanotan II ozna\u010duje aj ako MT-II alebo MTII a pou\u017e\u00edva sa najm\u00e4 ako experiment\u00e1lny ligand pri \u0161t\u00fadiu receptorov MC1R, MC3R, MC4R a MC5R.<\/p>\n<p>Pri interpret\u00e1cii publikovan\u00fdch v\u00fdsledkov je d\u00f4le\u017eit\u00e9 rozli\u0161ova\u0165 medzi <strong>endog\u00e9nnym \u03b1-MSH, syntetick\u00fdm Melanotan II, \u010fal\u0161\u00edmi melanokort\u00ednov\u00fdmi anal\u00f3gmi a konkr\u00e9tnym research-grade materi\u00e1lom<\/strong>. V\u00fdsledky z\u00edskan\u00e9 v receptorovom, bunkovom, zvieracom alebo historickom klinickom experimente nemo\u017eno automaticky pren\u00e1\u0161a\u0165 na samostatn\u00fa komer\u010dne dostupn\u00fa laborat\u00f3rnu \u0161ar\u017eu.<\/p>\n<div style=\"background: #eef7fc; border-left: 4px solid #55a7d9; padding: 18px 20px; margin: 25px 0; border-radius: 6px;\"><strong>Stru\u010dne:<\/strong> Melanotan II je syntetick\u00fd cyklick\u00fd heptapeptidov\u00fd anal\u00f3g \u03b1-MSH. Experiment\u00e1lny v\u00fdskum sa venuje predov\u0161etk\u00fdm melanokort\u00ednov\u00fdm receptorom, \u0161trukt\u00farno-funk\u010dn\u00fdm vz\u0165ahom peptidu, receptorovej afinite, analytickej detekcii a biologick\u00fdm odpovediam v presne definovan\u00fdch modeloch. Tieto \u00fadaje nepredstavuj\u00fa odpor\u00fa\u010danie na hum\u00e1nne pou\u017eitie ani d\u00f4kaz bezpe\u010dnosti konkr\u00e9tneho research-grade materi\u00e1lu.<\/div>\n<div style=\"background: #f7f9fb; border: 1px solid #e1e7ec; padding: 20px 24px; margin: 25px 0; border-radius: 6px;\"><strong>Obsah \u010dl\u00e1nku<\/strong><\/p>\n<ul style=\"margin: 12px 0 0 20px;\">\n<li><a href=\"#co-je-melanotan-ii\">\u010co je Melanotan II?<\/a><\/li>\n<li><a href=\"#struktura-melanotan-ii\">Cyklick\u00e1 \u0161trukt\u00fara Melanotan II<\/a><\/li>\n<li><a href=\"#alpha-msh-melanotan\">Melanotan II a \u03b1-MSH<\/a><\/li>\n<li><a href=\"#melanokortinove-receptory\">Melanokort\u00ednov\u00e9 receptory MC1R\u2013MC5R<\/a><\/li>\n<li><a href=\"#receptorovy-vyskum\">\u010co uk\u00e1zali receptorov\u00e9 experimenty?<\/a><\/li>\n<li><a href=\"#ludsky-vyskum-melanotan\">Historick\u00e9 \u013eudsk\u00e9 experiment\u00e1lne \u00fadaje<\/a><\/li>\n<li><a href=\"#analyticka-detekcia\">LC-MS\/MS a analytick\u00e1 detekcia<\/a><\/li>\n<li><a href=\"#uroven-dokazov-melanotan\">\u00darove\u0148 vedeck\u00fdch d\u00f4kazov<\/a><\/li>\n<li><a href=\"#regulacny-kontext-melanotan\">Regula\u010dn\u00fd kontext<\/a><\/li>\n<li><a href=\"#research-grade-melanotan\">Research-grade materi\u00e1l a COA<\/a><\/li>\n<li><a href=\"#limity-melanotan\">\u010co dostupn\u00fd v\u00fdskum nepreukazuje?<\/a><\/li>\n<li><a href=\"#faq-melanotan\">FAQ<\/a><\/li>\n<li><a href=\"#zdroje-melanotan\">Vedeck\u00e9 a regula\u010dn\u00e9 zdroje<\/a><\/li>\n<\/ul>\n<\/div>\n<h2 id=\"co-je-melanotan-ii\">\u010co je Melanotan II?<\/h2>\n<p><strong>Melanotan II (MT-II)<\/strong> je syntetick\u00fd cyklick\u00fd peptid odvoden\u00fd od biologicky akt\u00edvnej oblasti \u03b1-MSH. Patr\u00ed medzi melanokort\u00ednov\u00e9 anal\u00f3gy pou\u017e\u00edvan\u00e9 v experiment\u00e1lnom v\u00fdskume receptorovej farmakol\u00f3gie a \u0161trukt\u00farno-funk\u010dn\u00fdch vlastnost\u00ed melanokort\u00ednov\u00e9ho syst\u00e9mu.<\/p>\n<p>Datab\u00e1za PubChem uv\u00e1dza pre Melanotan II molekulov\u00fd vzorec <strong>C\u2085\u2080H\u2086\u2089N\u2081\u2085O\u2089<\/strong>, relat\u00edvnu molekulov\u00fa hmotnos\u0165 pribli\u017ene <strong>1024,2 g\/mol<\/strong> a CAS <strong>121062-08-6<\/strong>.<\/p>\n<p>Technick\u00fd zdroj:<\/p>\n<p><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/melanotan-II\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>PubChem \u2013 Melanotan II<\/strong><\/a>.<\/p>\n<div style=\"overflow-x: auto; margin: 25px 0;\">\n<table style=\"width: 100%; border-collapse: collapse; background: #eef7fc; border: 1px solid #c9e3f2;\">\n<thead>\n<tr style=\"background: #dceff9;\">\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Parameter<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">V\u00fdskumn\u00e1 charakteristika<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>N\u00e1zov<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Melanotan II \/ Melanotan-II \/ MT-II \/ MTII<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Typ molekuly<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Syntetick\u00fd cyklick\u00fd heptapeptidov\u00fd anal\u00f3g \u03b1-MSH<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Sekven\u010dn\u00fd z\u00e1pis<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH\u2082<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>CAS<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">121062-08-6<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Molekulov\u00e1 hmotnos\u0165<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">pribli\u017ene 1024,2 g\/mol<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Receptorov\u00fd kontext<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Melanokort\u00ednov\u00e9 receptory, najm\u00e4 MC1R, MC3R, MC4R a MC5R<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>V\u00fdskumn\u00e9 oblasti<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Receptorov\u00e1 farmakol\u00f3gia, melanokort\u00ednov\u00e1 signaliz\u00e1cia, analytick\u00e1 ch\u00e9mia a \u0161trukt\u00farno-funk\u010dn\u00fd v\u00fdskum<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Skladovanie<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Pod\u013ea etikety a CoA konkr\u00e9tnej research-grade \u0161ar\u017ee<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Ur\u010denie<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Research Use Only (RUO) \u2013 laborat\u00f3rny a analytick\u00fd v\u00fdskum<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 id=\"struktura-melanotan-ii\">Cyklick\u00e1 \u0161trukt\u00fara Melanotan II<\/h2>\n<p>Jednou z charakteristick\u00fdch vlastnost\u00ed MT-II je jeho <strong>cyklick\u00e1 lakt\u00e1mov\u00e1 \u0161trukt\u00fara<\/strong>. Cyklick\u00e9 usporiadanie bolo navrhnut\u00e9 v r\u00e1mci v\u00fdvoja anal\u00f3gov biologicky akt\u00edvnej \u010dasti \u03b1-MSH.<\/p>\n<p>Oproti line\u00e1rnemu prirodzen\u00e9mu peptidu obsahuje Melanotan II aj aminokyselinov\u00e9 modifik\u00e1cie vr\u00e1tane norleuc\u00ednu a D-fenylalan\u00ednu.<\/p>\n<p>Tak\u00e9to \u0161trukt\u00farne zmeny s\u00fa d\u00f4le\u017eit\u00e9 pri v\u00fdskume vz\u0165ahu medzi:<\/p>\n<ul>\n<li>konform\u00e1ciou peptidu,<\/li>\n<li>receptorovou afinitou,<\/li>\n<li>selektivitou medzi receptorov\u00fdmi podtypmi,<\/li>\n<li>a stabilitou molekuly v experiment\u00e1lnych syst\u00e9moch.<\/li>\n<\/ul>\n<p>Pri analytickom porovn\u00e1van\u00ed je preto d\u00f4le\u017eit\u00e9 nepracova\u0165 iba s n\u00e1zvom \u201eMelanotan II\u201c, ale overi\u0165 aj konkr\u00e9tnu molekulov\u00fa identitu sk\u00famanej vzorky.<\/p>\n<h2 id=\"alpha-msh-melanotan\">Melanotan II a \u03b1-MSH<\/h2>\n<p><strong>\u03b1-MSH<\/strong> patr\u00ed medzi endog\u00e9nne melanokort\u00ednov\u00e9 peptidy odvoden\u00e9 od prekurzora proopiomelanokort\u00ednu (POMC).<\/p>\n<p>Melanotan II bol vytvoren\u00fd ako syntetick\u00fd anal\u00f3g biologicky akt\u00edvnej oblasti \u03b1-MSH. To v\u0161ak neznamen\u00e1, \u017ee ide o identick\u00fa molekulu alebo \u017ee v\u0161etky vlastnosti prirodzen\u00e9ho \u03b1-MSH mo\u017eno automaticky prip\u00edsa\u0165 MT-II.<\/p>\n<div style=\"overflow-x: auto; margin: 25px 0;\">\n<table style=\"width: 100%; border-collapse: collapse; background: #eef7fc; border: 1px solid #c9e3f2;\">\n<thead>\n<tr style=\"background: #dceff9;\">\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Molekula<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Charakteristika<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Interpret\u00e1cia<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>\u03b1-MSH<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Endog\u00e9nny melanokort\u00ednov\u00fd peptid.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Prirodzen\u00fd ligand melanokort\u00ednov\u00e9ho syst\u00e9mu.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Melanotan II<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Syntetick\u00fd cyklick\u00fd anal\u00f3g \u010dasti \u03b1-MSH.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Experiment\u00e1lny ligand s odli\u0161nou \u0161trukt\u00farou a receptorov\u00fdm profilom.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Research-grade MT-II<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Konkr\u00e9tna syntetick\u00e1 \u0161ar\u017ea laborat\u00f3rneho materi\u00e1lu.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Identitu, \u010distotu a mno\u017estvo je potrebn\u00e9 overova\u0165 samostatnou analytickou dokument\u00e1ciou.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 id=\"melanokortinove-receptory\">Melanokort\u00ednov\u00e9 receptory MC1R\u2013MC5R<\/h2>\n<p>Melanokort\u00ednov\u00fd receptorov\u00fd syst\u00e9m pozost\u00e1va z viacer\u00fdch G-prote\u00ednov\u00fdch receptorov ozna\u010dovan\u00fdch MC1R a\u017e MC5R.<\/p>\n<p>Pri Melanotan II sa experiment\u00e1lna literat\u00fara venuje najm\u00e4 v\u00e4zbe a aktivite na receptoroch <strong>MC1R, MC3R, MC4R a MC5R<\/strong>. MT-II sa preto nepova\u017euje za vysoko selekt\u00edvny ligand jedn\u00e9ho receptorov\u00e9ho podtypu.<\/p>\n<p>Receptorov\u00e9 \u0161t\u00fadie umo\u017e\u0148uj\u00fa porovn\u00e1va\u0165, ako \u0161trukt\u00farne zmeny melanokort\u00ednov\u00fdch anal\u00f3gov menia ich afinitu a selektivitu medzi jednotliv\u00fdmi receptorov\u00fdmi podtypmi.<\/p>\n<p>Prim\u00e1rny zdroj:<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9357059\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Selectivity of cyclic MSH analogues for melanocortin receptor subtypes<\/strong><\/a>.<\/p>\n<h2 id=\"receptorovy-vyskum\">\u010co uk\u00e1zali receptorov\u00e9 experimenty?<\/h2>\n<p>Experimenty s bunkami exprimuj\u00facimi jednotliv\u00e9 \u013eudsk\u00e9 melanokort\u00ednov\u00e9 receptory uk\u00e1zali, \u017ee cyklick\u00e9 MSH anal\u00f3gy vr\u00e1tane MT-II vykazuj\u00fa vysok\u00fa receptorov\u00fa afinitu, pri\u010dom ich profil nie je obmedzen\u00fd na jedin\u00fd receptor.<\/p>\n<p>Tak\u00e9to \u00fadaje s\u00fa d\u00f4le\u017eit\u00e9 najm\u00e4 pri:<\/p>\n<ul>\n<li>charakteriz\u00e1cii receptorov\u00fdch ligandov,<\/li>\n<li>porovn\u00e1van\u00ed agonistov a antagonistov,<\/li>\n<li>v\u00fdvoji selekt\u00edvnej\u0161\u00edch experiment\u00e1lnych anal\u00f3gov,<\/li>\n<li>a \u0161t\u00fadiu \u0161trukt\u00farnych prvkov potrebn\u00fdch na v\u00e4zbu k melanokort\u00ednov\u00fdm receptorom.<\/li>\n<\/ul>\n<div style=\"background: #fff8dc; border: 1px solid #eadb99; border-left: 5px solid #d6b94c; padding: 18px 20px; margin: 25px 0; border-radius: 6px;\"><strong>D\u00f4le\u017eit\u00e1 interpret\u00e1cia:<\/strong><\/p>\n<p>Receptorov\u00e1 afinita alebo agonistick\u00e1 aktivita meran\u00e1 v bunkovom syst\u00e9me je mechanistick\u00fd \u00fadaj. Sama osebe nepreukazuje klinick\u00fa bezpe\u010dnos\u0165, \u00fa\u010dinnos\u0165 ani vhodnos\u0165 konkr\u00e9tneho pou\u017eitia u \u010dloveka.<\/p><\/div>\n<h2 id=\"ludsky-vyskum-melanotan\">Historick\u00e9 \u013eudsk\u00e9 experiment\u00e1lne \u00fadaje<\/h2>\n<p>Melanotan II bol predmetom aj ve\u013emi skor\u00e9ho pilotn\u00e9ho experiment\u00e1lneho v\u00fdskumu u \u013eud\u00ed.<\/p>\n<p>V roku 1996 bola publikovan\u00e1 mal\u00e1 f\u00e1za I zah\u0155\u0148aj\u00faca iba <strong>troch zdrav\u00fdch mu\u017esk\u00fdch dobrovo\u013en\u00edkov<\/strong>. V\u00fdskumn\u00edci sledovali biologick\u00fa odpove\u010f a toleranciu MT-II v kontrolovanom protokole.<\/p>\n<p>V \u0161t\u00fadii boli zaznamenan\u00e9 zmeny pigment\u00e1cie a z\u00e1rove\u0148 viacer\u00e9 ne\u017eiaduce prejavy vr\u00e1tane nevo\u013enosti, \u00fanavy a \u010fal\u0161\u00edch fyziologick\u00fdch reakci\u00ed.<\/p>\n<p>Prim\u00e1rny zdroj:<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8637402\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Dorr et al. \u2013 Evaluation of melanotan-II in a pilot phase-I clinical study<\/strong><\/a>.<\/p>\n<p>T\u00e1to historick\u00e1 pr\u00e1ca je d\u00f4le\u017eit\u00e1 pre pochopenie v\u00fdvoja molekuly, ale jej ve\u013ekos\u0165 a charakter neumo\u017e\u0148uj\u00fa interpretova\u0165 ju ako d\u00f4kaz v\u0161eobecnej klinickej bezpe\u010dnosti alebo schv\u00e1len\u00e9ho medic\u00ednskeho pou\u017eitia.<\/p>\n<h2 id=\"analyticka-detekcia\">LC-MS\/MS a analytick\u00e1 detekcia Melanotan II<\/h2>\n<p>MT-II sa pou\u017e\u00edval aj ako analytick\u00fd model pri v\u00fdvoji met\u00f3d hmotnostnej spektrometrie.<\/p>\n<p>Publikovan\u00e1 pr\u00e1ca z roku 2007 opisuje kvantitat\u00edvnu met\u00f3du zalo\u017een\u00fa na <strong>kvapalinovej chromatografii spojenej s tandemovou hmotnostnou spektrometriou (LC-MS\/MS)<\/strong>.<\/p>\n<p>Autori met\u00f3du pou\u017eili na stanovenie MT-II v plazme a mozgovom tkanive my\u0161\u00ed po experiment\u00e1lnej expoz\u00edcii.<\/p>\n<p>Prim\u00e1rny zdroj:<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17610239\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>LC-MS\/MS quantification of Melanotan-II in plasma and brain tissue<\/strong><\/a>.<\/p>\n<p>Tak\u00e9to analytick\u00e9 pr\u00e1ce pom\u00e1haj\u00fa charakterizova\u0165 detekciu a distrib\u00faciu molekuly v konkr\u00e9tnom experiment\u00e1lnom modeli. Nehovoria v\u0161ak automaticky ni\u010d o \u010distote alebo mno\u017estve inej komer\u010dne dostupnej \u0161ar\u017ee.<\/p>\n<h2 id=\"uroven-dokazov-melanotan\">\u00darove\u0148 vedeck\u00fdch d\u00f4kazov<\/h2>\n<div style=\"overflow-x: auto; margin: 25px 0;\">\n<table style=\"width: 100%; border-collapse: collapse; background: #eef7fc; border: 1px solid #c9e3f2;\">\n<thead>\n<tr style=\"background: #dceff9;\">\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Typ \u00fadajov<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">\u010co mo\u017eno sk\u00fama\u0165<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Hlavn\u00e9 obmedzenie<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Receptorov\u00e9 bunkov\u00e9 modely<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">MC1R, MC3R, MC4R, MC5R, afinita a receptorov\u00e1 aktivita.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Mechanistick\u00fd \u00fadaj, nie klinick\u00fd v\u00fdsledok.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Zvieracie modely<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Distrib\u00facia, receptorov\u00e9 mechanizmy a \u010fal\u0161ie fyziologick\u00e9 odpovede.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">V\u00fdsledky nemo\u017eno automaticky prenies\u0165 na \u010dloveka.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Pilotn\u00e9 \u013eudsk\u00e9 \u00fadaje<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Skor\u00e1 f\u00e1za I s ve\u013emi mal\u00fdm po\u010dtom \u00fa\u010dastn\u00edkov.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Nedostato\u010dn\u00e9 na potvrdenie v\u0161eobecnej bezpe\u010dnosti alebo schv\u00e1len\u00e9ho pou\u017eitia.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>LC-MS\/MS<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Analytick\u00e1 identifik\u00e1cia a kvantifik\u00e1cia v experiment\u00e1lnych vzork\u00e1ch.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Nevypoved\u00e1 automaticky o kvalite inej \u0161ar\u017ee.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Research-grade COA<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Identita, chromatografick\u00e1 \u010distota a mno\u017estvo konkr\u00e9tnej \u0161ar\u017ee.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Nepredstavuje d\u00f4kaz klinickej bezpe\u010dnosti alebo \u00fa\u010dinnosti.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 id=\"regulacny-kontext-melanotan\">Regula\u010dn\u00fd kontext Melanotan II<\/h2>\n<p>Melanotan II nem\u00e1 by\u0165 zamie\u0148an\u00fd s regula\u010dne schv\u00e1len\u00fdm liekom alebo spotrebite\u013esk\u00fdm produktom.<\/p>\n<p>Americk\u00fd FDA vo svojich historick\u00fdch regula\u010dn\u00fdch a enforcement dokumentoch ozna\u010dil Melanotan II pred\u00e1van\u00fd na hum\u00e1nne pou\u017eitie za <strong>unapproved new drug<\/strong>. FDA z\u00e1rove\u0148 rie\u0161ila pr\u00edpady, ke\u010f bol materi\u00e1l ozna\u010den\u00fd ako \u201eresearch use only\u201c, ale marketing alebo sp\u00f4sob predaja smeroval k hum\u00e1nnemu pou\u017e\u00edvaniu.<\/p>\n<p>Ofici\u00e1lne zdroje:<\/p>\n<p><a href=\"https:\/\/www.fda.gov\/regulatory-information\/electronic-reading-room\/notice-opportunity-hearing-nooh-manookian-edward-8516\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>FDA \u2013 Melanotan II regulatory enforcement record<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/doj-press-releases-involving-fda-oci\/may-9-2016-owner-bodybuilding-drug-companies-sentenced-selling-misbranded-drugs\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>FDA \u2013 enforcement involving products including Melanotan II<\/strong><\/a><\/p>\n<div style=\"background: #fff8dc; border: 1px solid #eadb99; border-left: 5px solid #d6b94c; padding: 18px 20px; margin: 25px 0; border-radius: 6px;\"><strong>Praktick\u00fd v\u00fdznam pre research-grade str\u00e1nku:<\/strong><\/p>\n<p>Ozna\u010denie Research Use Only m\u00e1 by\u0165 podporen\u00e9 aj obsahom str\u00e1nky. Produktov\u00e9 a informa\u010dn\u00e9 texty by preto nemali obsahova\u0165 d\u00e1vkovanie, n\u00e1vody na osobn\u00fa aplik\u00e1ciu alebo spotrebite\u013esk\u00e9 tvrdenia o v\u00fdsledkoch na \u013eudskom tele.<\/p><\/div>\n<h2 id=\"research-grade-melanotan\">Research-grade Melanotan II a analytick\u00e1 dokument\u00e1cia<\/h2>\n<p>Vedeck\u00e1 publik\u00e1cia opisuje molekulu pou\u017eit\u00fa v konkr\u00e9tnom experiment\u00e1lnom protokole. Nepotvrdzuje automaticky kvalitu samostatnej komer\u010dne dostupnej \u0161ar\u017ee.<\/p>\n<p>Pri hodnoten\u00ed research-grade Melanotan II s\u00fa relevantn\u00e9 najm\u00e4:<\/p>\n<ul>\n<li>presn\u00e1 molekulov\u00e1 identita,<\/li>\n<li>cyklick\u00e1 forma peptidu,<\/li>\n<li>zodpovedaj\u00faca molekulov\u00e1 hmotnos\u0165,<\/li>\n<li>chromatografick\u00e1 \u010distota,<\/li>\n<li>kvantitat\u00edvne stanovenie mno\u017estva,<\/li>\n<li>\u010d\u00edslo \u0161ar\u017ee alebo lot number,<\/li>\n<li>pou\u017eit\u00e1 analytick\u00e1 met\u00f3da,<\/li>\n<li>doh\u013eadate\u013enos\u0165 COA ku konkr\u00e9tnej analyzovanej vzorke,<\/li>\n<li>podmienky skladovania uveden\u00e9 na etikete a v CoA konkr\u00e9tnej \u0161ar\u017ee.<\/li>\n<\/ul>\n<div style=\"background: #eef7fc; border-left: 4px solid #55a7d9; padding: 18px 20px; margin: 25px 0; border-radius: 6px;\"><strong>Analytick\u00e1 pozn\u00e1mka:<\/strong> HPLC area purity, molekulov\u00e1 identita a mno\u017estvo materi\u00e1lu vo vialke predstavuj\u00fa rozdielne analytick\u00e9 veli\u010diny. Vysok\u00e1 chromatografick\u00e1 \u010distota sama osebe nepotvrdzuje spr\u00e1vne mno\u017estvo, stabilitu ani biologick\u00fa alebo klinick\u00fa bezpe\u010dnos\u0165 vzorky.<\/div>\n<p>Viac o hodnoten\u00ed \u010distoty, \u0161ar\u017e\u00ed a dokument\u00e1cie n\u00e1jdete v \u010dl\u00e1nku <a href=\"https:\/\/nexxusbio.com\/7-kriterii-vyberu-peptidoveho-dodavatela\/\"><strong>7 krit\u00e9ri\u00ed v\u00fdberu peptidov\u00e9ho dod\u00e1vate\u013ea<\/strong><\/a>.<\/p>\n<p>Dokument\u00e1ciu dostupn\u00fa pre analyzovan\u00e9 \u0161ar\u017ee mo\u017eno overova\u0165 aj v sekcii <a href=\"https:\/\/nexxusbio.com\/coa\/\"><strong>COA a analytick\u00e1 dokument\u00e1cia<\/strong><\/a>.<\/p>\n<h2 id=\"limity-melanotan\">\u010co dostupn\u00fd v\u00fdskum nepreukazuje?<\/h2>\n<p>Pri Melanotan II je potrebn\u00e9 d\u00f4sledne odli\u0161ova\u0165 experiment\u00e1lnu receptorov\u00fa farmakol\u00f3giu od spotrebite\u013esk\u00fdch tvrden\u00ed.<\/p>\n<p>Dostupn\u00e9 \u00fadaje samy osebe nepreukazuj\u00fa:<\/p>\n<ul>\n<li>klinick\u00fa bezpe\u010dnos\u0165 komer\u010dn\u00e9ho research-grade Melanotan II,<\/li>\n<li>vhodnos\u0165 materi\u00e1lu na osobn\u00e9 alebo hum\u00e1nne pou\u017eitie,<\/li>\n<li>\u017ee v\u00fdsledky receptorov\u00fdch bunkov\u00fdch experimentov predstavuj\u00fa zdravotn\u00fd benefit,<\/li>\n<li>\u017ee v\u00fdsledky zo zvierac\u00edch modelov automaticky platia pre \u010dloveka,<\/li>\n<li>\u017ee pilotn\u00e1 \u0161t\u00fadia s tromi \u00fa\u010dastn\u00edkmi predstavuje d\u00f4kaz v\u0161eobecnej klinickej bezpe\u010dnosti,<\/li>\n<li>\u017ee materi\u00e1l z vedeckej \u0161t\u00fadie je toto\u017en\u00fd s \u013eubovo\u013enou komer\u010dne dostupnou \u0161ar\u017eou,<\/li>\n<li>\u017ee \u00fadaj o HPLC \u010distote je d\u00f4kazom bezpe\u010dnosti alebo \u00fa\u010dinnosti.<\/li>\n<\/ul>\n<p>Pre research-grade informa\u010dn\u00fa str\u00e1nku preto nie je vhodn\u00e9 pou\u017e\u00edva\u0165 spotrebite\u013esk\u00e9 formul\u00e1cie typu \u201er\u00fdchle op\u00e1lenie\u201c, \u201etanning peptide\u201c, \u201ezvy\u0161uje libido\u201c, \u201espa\u013eovanie tuku\u201c alebo in\u00e9 tvrdenia smeruj\u00face k v\u00fdsledku na \u013eudskom tele.<\/p>\n<h2>Ako kriticky \u010d\u00edta\u0165 \u0161t\u00fadie o Melanotan II?<\/h2>\n<p>Pri ka\u017edej publik\u00e1cii je vhodn\u00e9 overi\u0165:<\/p>\n<ul>\n<li>\u010di bol pou\u017eit\u00fd MT-II alebo in\u00fd \u03b1-MSH anal\u00f3g,<\/li>\n<li>ktor\u00fd melanokort\u00ednov\u00fd receptor bol sk\u00faman\u00fd,<\/li>\n<li>\u010di i\u0161lo o bunkov\u00fd, zvierac\u00ed alebo \u013eudsk\u00fd model,<\/li>\n<li>ve\u013ekos\u0165 experiment\u00e1lneho s\u00faboru,<\/li>\n<li>\u010di sa sledovala receptorov\u00e1 afinita, biologick\u00e1 odpove\u010f alebo analytick\u00e1 distrib\u00facia,<\/li>\n<li>\u010di ide o prim\u00e1rnu experiment\u00e1lnu \u0161t\u00fadiu alebo preh\u013eadov\u00fd \u010dl\u00e1nok,<\/li>\n<li>a \u010di v\u00fdsledok mo\u017eno reprodukova\u0165 v nez\u00e1vislom modeli.<\/li>\n<\/ul>\n<p>Tak\u00fdto pr\u00edstup pom\u00e1ha oddeli\u0165 molekul\u00e1rny mechanizmus od tvrdenia, ktor\u00e9 by presahovalo publikovan\u00e9 \u00fadaje.<\/p>\n<h2 id=\"faq-melanotan\">FAQ \u2013 Melanotan II v\u00fdskum<\/h2>\n<h3>\u010co je Melanotan II?<\/h3>\n<p>Melanotan II je syntetick\u00fd cyklick\u00fd heptapeptidov\u00fd anal\u00f3g biologicky akt\u00edvnej oblasti \u03b1-MSH. Vo v\u00fdskume sa pou\u017e\u00edva predov\u0161etk\u00fdm pri \u0161t\u00fadiu melanokort\u00ednov\u00fdch receptorov a receptorovej signaliz\u00e1cie.<\/p>\n<h3>Je Melanotan II rovnak\u00fd ako \u03b1-MSH?<\/h3>\n<p>Nie. \u03b1-MSH je endog\u00e9nny melanokort\u00ednov\u00fd peptid, zatia\u013e \u010do Melanotan II je syntetick\u00fd cyklick\u00fd anal\u00f3g s viacer\u00fdmi \u0161trukt\u00farnymi modifik\u00e1ciami.<\/p>\n<h3>Ktor\u00e9 receptory sa pri Melanotan II sk\u00famaj\u00fa?<\/h3>\n<p>Publikovan\u00e9 receptorov\u00e9 pr\u00e1ce hodnotili najm\u00e4 MC1R, MC3R, MC4R a MC5R. MT-II nie je vysoko selekt\u00edvny iba pre jeden z t\u00fdchto receptorov\u00fdch podtypov.<\/p>\n<h3>Existuj\u00fa \u013eudsk\u00e9 \u0161t\u00fadie Melanotan II?<\/h3>\n<p>\u00c1no. V roku 1996 bola publikovan\u00e1 mal\u00e1 pilotn\u00e1 f\u00e1za I s tromi zdrav\u00fdmi mu\u017emi. Takto mal\u00fd experiment v\u0161ak nemo\u017eno interpretova\u0165 ako potvrdenie v\u0161eobecnej bezpe\u010dnosti alebo schv\u00e1len\u00e9ho klinick\u00e9ho pou\u017eitia.<\/p>\n<h3>Na \u010do sa pou\u017e\u00edva LC-MS\/MS pri Melanotan II?<\/h3>\n<p>LC-MS\/MS mo\u017eno pou\u017ei\u0165 na analytick\u00fa identifik\u00e1ciu a kvantifik\u00e1ciu MT-II v experiment\u00e1lnych vzork\u00e1ch. Analytick\u00e1 met\u00f3da v\u0161ak sama osebe nepreukazuje klinick\u00fa bezpe\u010dnos\u0165 alebo \u00fa\u010dinnos\u0165.<\/p>\n<h3>Sta\u010d\u00ed pri research-grade MT-II \u00fadaj o HPLC \u010distote?<\/h3>\n<p>Nie. Chromatografick\u00e1 \u010distota je iba jeden parameter. Molekulov\u00e1 identita, mno\u017estvo, \u0161ar\u017ea, forma materi\u00e1lu a \u010fal\u0161ie analytick\u00e9 \u00fadaje sa musia hodnoti\u0165 samostatne.<\/p>\n<h3>Ako sa Melanotan II skladuje?<\/h3>\n<p>Research-grade materi\u00e1l sa m\u00e1 skladova\u0165 pod\u013ea \u00fadajov uveden\u00fdch na etikete a v CoA konkr\u00e9tnej \u0161ar\u017ee. Pri konkr\u00e9tnom produkte maj\u00fa v\u017edy prednos\u0165 batch-specific technick\u00e9 podmienky.<\/p>\n<p>\u010eal\u0161\u00ed odborn\u00fd obsah n\u00e1jdete v sekcii <a href=\"https:\/\/nexxusbio.com\/category\/vyskum-peptidov\/\"><strong>V\u00fdskum peptidov<\/strong><\/a>.<\/p>\n<h2 id=\"zdroje-melanotan\">Vedeck\u00e9 a regula\u010dn\u00e9 zdroje<\/h2>\n<ol>\n<li>PubChem.<br \/>\n<em>Melanotan II \u2013 CID 92432.<\/em><br \/>\n<a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/melanotan-II\" target=\"_blank\" rel=\"noopener noreferrer\">PubChem<\/a><\/li>\n<li>Schi\u00f6th HB, Muceniece R, Wikberg JES.<br \/>\n<em>Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes.<\/em><br \/>\nPeptides. 1997.<br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9357059\/\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed<\/a><\/li>\n<li>Dorr RT, Lines R, Levine N, et al.<br \/>\n<em>Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.<\/em><br \/>\nLife Sciences. 1996.<br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8637402\/\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed<\/a><\/li>\n<li><em>A liquid chromatographic\/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II.<\/em><br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17610239\/\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed<\/a><\/li>\n<li>U.S. Food and Drug Administration.<br \/>\n<em>Regulatory enforcement record concerning Melanotan II.<\/em><br \/>\n<a href=\"https:\/\/www.fda.gov\/regulatory-information\/electronic-reading-room\/notice-opportunity-hearing-nooh-manookian-edward-8516\" target=\"_blank\" rel=\"noopener noreferrer\">FDA<\/a><\/li>\n<\/ol>\n<div style=\"background: #fff8dc; border: 1px solid #eadb99; border-left: 5px solid #d6b94c; padding: 18px 20px; margin: 30px 0; border-radius: 6px;\"><strong>D\u00f4le\u017eit\u00e9 upozornenie:<\/strong><\/p>\n<p>Tento \u010dl\u00e1nok sl\u00fa\u017ei v\u00fdhradne na informa\u010dn\u00e9, vzdel\u00e1vacie a vedeck\u00e9 \u00fa\u010dely. Inform\u00e1cie opisuj\u00fa molekul\u00e1rne, receptorov\u00e9, analytick\u00e9, predklinick\u00e9 a historick\u00e9 experiment\u00e1lne \u00fadaje. Nejde o lek\u00e1rske odpor\u00fa\u010danie, diagnostiku, prevenciu ani n\u00e1vod na lie\u010dbu.<\/p>\n<p>V\u00fdsledky receptorov\u00fdch, bunkov\u00fdch alebo zvierac\u00edch experimentov nemo\u017eno automaticky interpretova\u0165 ako potvrden\u00fd zdravotn\u00fd alebo klinick\u00fd \u00fa\u010dinok u \u010dloveka. Ani historick\u00e9 pilotn\u00e9 \u013eudsk\u00e9 experimenty nepreukazuj\u00fa bezpe\u010dnos\u0165 alebo \u00fa\u010dinnos\u0165 konkr\u00e9tneho komer\u010dne dostupn\u00e9ho research-grade materi\u00e1lu.<\/p>\n<p>Research-grade Melanotan II a ostatn\u00e9 materi\u00e1ly prezentovan\u00e9 na str\u00e1nke NEXXUS BIO s\u00fa ur\u010den\u00e9 v\u00fdhradne na laborat\u00f3rne, analytick\u00e9 a vedeck\u00e9 \u00fa\u010dely (Research Use Only). Nie s\u00fa ur\u010den\u00e9 na hum\u00e1nne ani veterin\u00e1rne pou\u017eitie, konzum\u00e1ciu, osobn\u00fa aplik\u00e1ciu, diagnostiku, prevenciu alebo lie\u010dbu.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Melanotan II v\u00fdskumn\u00e9 pou\u017eitie v laborat\u00f3riu vy\u017eaduje presn\u00fa dokument\u00e1ciu, \u010distotu \u0161ar\u017e\u00ed, COA a jasn\u00e9 oddelenie od hum\u00e1nneho pou\u017eitia.<\/p>","protected":false},"author":2,"featured_media":10628,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[194],"tags":[],"class_list":["post-10627","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vyskum-peptidov"],"_links":{"self":[{"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/posts\/10627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/comments?post=10627"}],"version-history":[{"count":3,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/posts\/10627\/revisions"}],"predecessor-version":[{"id":10769,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/posts\/10627\/revisions\/10769"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/media\/10628"}],"wp:attachment":[{"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/media?parent=10627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/categories?post=10627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/tags?post=10627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}